# To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects

> **NCT07030504** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** SAL0133
- **DRUG:** SAL0133 placebo

## Key facts

- **NCT ID:** NCT07030504
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-10
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030504, "To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07030504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*